Bioclinica ramps up patient engagement with new divisions

Doctor-patient

Bioclinica is set to unveil two new divisions later this month that aim to create an “integrated offering focused on patient engagement.”

These new divisions will see it split its Research Network--which came as a result of its 2014 merger with CCBR-SYNARC--and its Patient Recruitment-Retention into two distinct offerings.  

The Research Network has an established system of investigator sites, and has worked on a number of therapy areas, including: Alzheimer's, cardiovascular, osteoarthritis, diabetes, vaccines and pain.

The Patient Recruitment-Retention division, which has been integrated into the company since the MediciGlobal acquisition in 2015, has a 94% overall success rate in patient recruitment and retention programs, according to Bioclinica, with more than 200 successfully completed programs in across a number of therapeutic areas.

This team has placed a major focus on social media and other digital strategies to help with patient recruitment, as well as developing this with “mobile engagement apps.” More than 30 patient communities have been established as a result, Bioclinica added in a statement.

"Our vibrant patient communities cross all key therapeutic areas and have a collective membership of hundreds of thousands of engaged potential study participants," Dr. John Hubbard, CEO and president of Bioclinica, said.

"These vast, active online communities are readily accessible to sponsors and CROs when a trial is ready to begin enrolling."

Its global clinical research president Elizabeth Thiele added: “Both the Research Network and Patient Recruitment-Retention divisions are hyper-focused on the patient and employ technology-enabled strategies. Having such strong patient engagement come from two sources within our expanding organization gives sponsors and CROs an inroad to qualified patients.”

Bioclinica said it will publically unveil the two new divisions at the DIA Annual Meeting to be held in Philadelphia at the end of June.

The company is said to be seeking a $1.3 billion deal to sell itself, according to people “familiar with the matter” speaking anonymously to Reuters, and comes after the company has been ramping up its own buys and pacts, including with consulting firm Kinapse to help spread the adoption of its Compass technology last year, and its acquisition of clinical trial financial specialist Clinverse back in January.

- check out the release

Related Articles:
Bioclinica seeking $1.3B sale: Reuters
BioClinica notches up another deal, this time with EPS

Suggested Articles

In March, the FDA urged biopharmas and CROs to take a virtual approach to clinical trials in reaction to COVID-19 and the attempt to slow its spread.

PRA Health has launched a new mobile app aimed at tracking patients’ physical and psychological symptoms from COVID-19.

Life science venture capital firm Syncona is warning of serious delays to studies across its biotech portfolio.